Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Peter Hillmen; John F Seymour; Steven Coutre; Wojciech Jurczak; Stephen P Mulligan; Anna Schuh; Sarit Assouline; Clemens-Martin Wendtner; Andrew W Roberts; Matthew S Davids; Johannes Bloehdorn; Talha Munir; Sebastian Boettcher; Lang Zhou; Ahmed Hamed Salem; Monali Desai; Brenda Chyla; Jennifer Arzt; Su Young Kim; Maria Verdugo; Gary Gordon; Michael Hallek; William G Wierda

Journal article

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F Seymour, Steven Coutre, Wojciech Jurczak, Stephen P Mulligan, Anna Schuh, Sarit Assouline, Clemens-Martin Wendtner, Andrew W Roberts, Matthew S Davids, Johannes Bloehdorn, Talha Munir, Sebastian Boettcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018

DOI: 10.1200/JCO.2017.76.6840

University of Melbourne Researchers

John Seymour Author Medicine - St Vincent's Hospital

Andrew Roberts Author

Grants

Funding Acknowledgements

Funded by AbbVie and Genentech. Venetoclax is being developed in collaboration between AbbVie and Genentech. AbbVie and Genentech provided financial support for the study and participated in the design, study conduct, analysis, and interpretation of data, as well as the writing, review, and approval of the manuscript.